Roche pads out obesity pipeline, paying Zealand $1.6B upfront to co-develop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline. The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to co-develop and co-commercialize Zealand Pharma’s long-acting amylin analog petrelintide.
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline. The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to co-develop and co-commercialize Zealand Pharma’s long-acting amylin analog petrelintide.
